HeberFERON, a combination of alfa-2b and gamma interferons, is a biopharmaceutical developed by the Center for Genetic Engineering and Biotechnology, Havana, Cuba, and approved by the Cuban regulatory authorities for the treatment of BCC.13 Here, IFNG is linked to skin basal cell carcinoma.